No intervention
OtherSample collection
NCT Number: NCT00677768
The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.
Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.
Looking for future studies?
Notify Me30 year–80 year
All sexes
Observational
Montreal Neurological Institute, Montreal, Quebec, Canada
Researchers tested what changes happen in volunteers with ALS that can be seen in the blood and what changes are unique to ALS and are different from those found in healthy volunteers and volunteers with neurological diseases other than ALS. These changes are called biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS easier. In the next phase, comparison of these changes in the blood of volunteers with ALS and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose and monitor progression of ALS.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Inclusion criteria
Exclusion criteria
Inclusion criteria
Diagnosis of one of the following:
Pure Lower Motor Neuron Disease (LMND) mimics:
Peripheral mononeuropathies:
Pure Upper Motor Neuron Disease (UMND) mimics:
Exclusion criteria
Exclusion criteria
Sample collection
Time frame: Every 6 months
The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
Massachusetts General Hospital
Other
A Multicenter Study for the Validation of ALS Biomarkers
Acronym: BIO_ALS-01
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03127514
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT02852278
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
View Trial DetailsNCT01495390
ALS, Amyotrophic Lateral Sclerosis
Phoenix, Arizona, United States
View Trial DetailsNCT00023075
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Bethesda, Maryland, United States
View Trial Details